• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增强的肾脏清除率。

Augmented Renal Clearance.

机构信息

UKHealthcare, Pharmacy Services, University of Kentucky, Lexington, Kentucky.

University of Kentucky College of Pharmacy, Pharmacy Practice and Science, Lexington, Kentucky.

出版信息

Pharmacotherapy. 2019 Mar;39(3):346-354. doi: 10.1002/phar.2231. Epub 2019 Mar 11.

DOI:10.1002/phar.2231
PMID:30723936
Abstract

Augmented renal clearance (ARC) is a phenomenon in critically ill patients characterized by increased creatinine clearance and elimination of renally eliminated medications. Patients with severe neurologic injury, sepsis, trauma, and burns have been consistently identified as at risk of ARC, with mean creatinine clearances ranging from 170 ml/minute to more than 300 ml/minute. Several potential mechanisms may contribute to the occurrence of ARC including endogenous responses to increased metabolism and solute production, alterations in neurohormonal balance, and therapeutic maneuvers such as fluid resuscitation. Augmented renal clearance is associated with suboptimal exposure to critical medications, including β-lactams and vancomycin, increasing the risk of treatment failure. Although definitive screening tools are not yet known, critical care pharmacists must be vigilant in recognizing when ARC may be a contributing factor affecting expected treatment outcomes in individual patients. Optimizing dosing strategies in critically ill patients with ARC remains a goal of continued research. The current review discusses the clinical characteristics and methods of identifying patients at risk of ARC, potential mechanisms for ARC, and describes pharmacotherapy dosing considerations in patients with ARC.

摘要

增强的肾清除率(ARC)是危重病患者的一种现象,其特征为肌酐清除率增加和肾排泄药物的消除。严重神经损伤、脓毒症、创伤和烧伤的患者一直被认为有 ARC 的风险,平均肌酐清除率从 170ml/min 到 300ml/min 以上。几种潜在的机制可能导致 ARC 的发生,包括对增加的代谢和溶质产生的内源性反应、神经激素平衡的改变以及液体复苏等治疗措施。ARC 与关键药物(包括β-内酰胺类和万古霉素)的暴露不足有关,增加了治疗失败的风险。尽管目前还没有明确的筛查工具,但重症监护药剂师必须警惕 ARC 可能是影响个体患者预期治疗结果的一个因素。优化 ARC 危重病患者的给药策略仍然是持续研究的目标。本综述讨论了识别 ARC 风险患者的临床特征和方法、ARC 的潜在机制,并描述了 ARC 患者的药物治疗剂量考虑因素。

相似文献

1
Augmented Renal Clearance.增强的肾脏清除率。
Pharmacotherapy. 2019 Mar;39(3):346-354. doi: 10.1002/phar.2231. Epub 2019 Mar 11.
2
Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?儿科重症监护中的增强肾清除率:我们是否对病情最严重的患者治疗不足?
Pediatr Nephrol. 2020 Jan;35(1):25-39. doi: 10.1007/s00467-018-4120-2. Epub 2018 Oct 29.
3
Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.肾功能增强对重症患者药物剂量的影响:聚焦于抗生素
Pharmacotherapy. 2015 Nov;35(11):1063-75. doi: 10.1002/phar.1653.
4
Prevalence and Risk Factors for Augmented Renal Clearance in a Population of Critically Ill Patients.危重症患者群体中增强型肾脏清除率的流行情况及危险因素。
J Intensive Care Med. 2020 Oct;35(10):1044-1052. doi: 10.1177/0885066618809688. Epub 2018 Oct 29.
5
Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients.血浆肌酐浓度正常的脓毒症和创伤患者的肾脏清除率增加:识别高危患者。
Crit Care. 2013 Feb 28;17(1):R35. doi: 10.1186/cc12544.
6
Augmented Renal Clearance in Critically Ill Patients: A Systematic Review.危重症患者的增强肾脏清除率:系统评价。
Clin Pharmacokinet. 2018 Sep;57(9):1107-1121. doi: 10.1007/s40262-018-0636-7.
7
Augmented Renal Clearance Following Traumatic Injury in Critically Ill Patients Requiring Nutrition Therapy.创伤后危重患者营养治疗时的增强肾清除率。
Nutrients. 2021 May 15;13(5):1681. doi: 10.3390/nu13051681.
8
Personalized application of antimicrobial drugs in pediatric patients with augmented renal clearance: a review of literature.肾功能增强的儿科患者抗菌药物的个体化应用:文献综述
Eur J Pediatr. 2024 Jan;183(1):51-60. doi: 10.1007/s00431-023-05272-x. Epub 2023 Oct 20.
9
Drug Utilization in Critically Ill Adults with Augmented Renal Clearance Compared to Normal Renal Clearance: Implications for use of Antimicrobials with Predominant Renal Excretion.增强肾清除率与正常肾清除率的危重病成人的药物利用:对主要经肾脏排泄的抗菌药物使用的影响。
Curr Rev Clin Exp Pharmacol. 2021;16(2):174-181. doi: 10.2174/1574884715666200810095225.
10
Select critically ill patients at risk of augmented renal clearance: experience in a Malaysian intensive care unit.筛选存在肾脏清除率增加风险的重症患者:马来西亚重症监护病房的经验
Anaesth Intensive Care. 2014 Nov;42(6):715-22. doi: 10.1177/0310057X1404200606.

引用本文的文献

1
Predicting 28-Day Mortality in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Novel Interpretable Machine Learning Approach.预测接受连续性肾脏替代治疗的重症患者的28天死亡率:一种新型可解释机器学习方法。
J Multidiscip Healthc. 2025 Sep 5;18:5535-5550. doi: 10.2147/JMDH.S533031. eCollection 2025.
2
Machine learning for the prediction of augmented renal clearance (ARC) in patients with sepsis in critical care units.用于预测重症监护病房脓毒症患者肾脏清除率增加(ARC)的机器学习
Sci Rep. 2025 Jul 18;15(1):26119. doi: 10.1038/s41598-025-11313-2.
3
The Definition, Prevalence, and Risk Factors of Augmented Renal Clearance in Adult Patients on Antimicrobial Therapy: A Scoping Review.
抗菌治疗成年患者中强化肾清除率的定义、患病率及危险因素:一项范围综述
Infect Dis Clin Microbiol. 2025 Jun 26;7(2):123-132. doi: 10.36519/idcm.2025.504. eCollection 2025 Jun.
4
producing AmpC DHA-1 bacteraemia in neutropenic leukemic patient: continuous infusion ceftazidime/avibactam as a carbapenem sparing regimen.在中性粒细胞减少的白血病患者中产生AmpC DHA-1菌血症:持续输注头孢他啶/阿维巴坦作为一种碳青霉烯类药物节省方案。
JAC Antimicrob Resist. 2025 Jun 18;7(3):dlaf109. doi: 10.1093/jacamr/dlaf109. eCollection 2025 Jun.
5
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing infections and on ceftazidime/avibactam resistance development.一项关于抗菌药物管理的前后对照准实验研究,探讨多学科方法的影响,该方法旨在通过头孢他啶/阿维巴坦实现积极的联合药代动力学/药效学目标,对产KPC感染的治疗结果以及头孢他啶/阿维巴坦耐药性发展的影响。
Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0048825. doi: 10.1128/aac.00488-25. Epub 2025 Jun 6.
6
Prevalence and Risk Factors for Augmented Renal Clearance in Neurocritical Ill Patients.神经重症患者肾脏清除率增加的患病率及危险因素
J Clin Lab Anal. 2025 Jun;39(11):e70047. doi: 10.1002/jcla.70047. Epub 2025 May 20.
7
Variability in Meropenem Distribution and Clearance in Children with Sepsis: Population-Based Pharmacokinetics with Assessment of Renal Biomarkers.脓毒症患儿美罗培南分布与清除的变异性:基于人群的药代动力学及肾脏生物标志物评估
Clin Pharmacokinet. 2025 May;64(5):769-777. doi: 10.1007/s40262-025-01495-3. Epub 2025 Apr 24.
8
Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns.两名全身大面积烧伤患者持续输注头孢洛扎/他唑巴坦的药代动力学
Pharmacotherapy. 2025 Jun;45(6):386-392. doi: 10.1002/phar.70019. Epub 2025 Apr 15.
9
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy useful for raising the bar?一项关于在治疗严重铜绿假单胞菌感染中,采用治疗药物监测(TDM)指导的持续输注头孢洛扎/他唑巴坦单药治疗的积极药代动力学/药效学目标达成情况影响的前后对照准实验研究:一种有助于提高标准的策略?
J Antimicrob Chemother. 2025 Mar 24;80(6):1543-51. doi: 10.1093/jac/dkaf098.
10
Pharmacokinetic variability and significance of therapeutic drug monitoring for broad-spectrum antimicrobials in critically ill patients.危重症患者中广谱抗菌药物的药代动力学变异性及治疗药物监测的意义
J Pharm Health Care Sci. 2025 Mar 17;11(1):21. doi: 10.1186/s40780-025-00425-6.